Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

NCT ID: NCT00262093

Last Updated: 2007-03-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.

We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Every delivery

Exclusion Criteria

* Preeclampsia or pregnancy induced hypertension
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role collaborator

Hadassah Medical Organization

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yuval Bdolah, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Hadassah-Hebrew University Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hadassah Medical Organization

Jerusalem, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuval Bdolah, MD, MSc

Role: CONTACT

972-2-5844111

Hadas Lemberg, PhD

Role: CONTACT

972-2-6777572

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Arik Tzukert, DMD

Role: primary

972 2 6776095

Hadas Lemberg, PhD

Role: backup

972 2 6777572

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRIMIMULTI-HMO-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PP13 and Doppler Study to Predict Preeclampsia
NCT00928213 UNKNOWN PHASE2/PHASE3
MR and Inflammation After Preeclampsia
NCT07345845 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Prenatal Aspirin and Postpartum Vascular Function
NCT05653973 RECRUITING EARLY_PHASE1